Label:informationpara thepatient
Desvenlafaxine Neuraxpharm 50 mg prolonged-release tablets EFG
Read this label carefully before starting to take this medication, because it contains important information for you.
Desvenlafaxina Neuraxpharm contains the active substance desvenlafaxine (as benzoate).
This medicine is an antidepressant that belongs to a group of medicines called serotonin and noradrenaline reuptake inhibitors (SNRIs).This group of medicines is used to treat depression.
The exact way in which antidepressants work is not fully understood, but they may help increase the levels of serotonin and noradrenaline in the brain.
Do not take Desvenlafaxina Neuraxpharm:
Warnings and precautions
Consult your doctor if you have had any of the following conditions before taking Desvenlafaxina or if they occur during treatment with this medication:
Some medications in the group to which Desvenlafaxina belongs (called SSRIs/SNRIs) may cause sexual dysfunction side effects (see section 4). In some cases, these side effects persist after stopping treatment.
Desvenlafaxina may cause restlessness or an inability to sit or remain still during the first weeks of treatment.You should inform your doctor if this happens.
Thoughts of suicide and worsening of your depression
If you are depressed, you may have had thoughts of harming yourself or suicide.These thoughts may increase when you start taking antidepressants, as these medications take time to work, usually two weeks, but sometimes longer.
You may be more likely to have these thoughts:
If you have thoughts of harming yourself or suicide at any time,contact your doctor or go to the hospital directly.
You may find it helpful to tell a close family member or friend who is depressed, and ask them to read this leaflet. You could also ask them to tell you if they think your depression or anxiety is getting worse, or if they are concerned about changes in your behavior.
Medications like desvenlafaxine (called SSRIs/SNRIs) may cause sexual dysfunction side effects (see section 4). In some cases, these side effects persist after stopping treatment.
Dry mouth
Dry mouth has been reported in 18% of patients treated with desvenlafaxine. This may increase the risk of tooth decay. Therefore, you should take good care of your oral hygiene.
Older patients
In some older patients, it cannot be ruled out that they may be more sensitive to desvenlafaxine.
Children and adolescents
This medication should not be used normally in children and adolescents under 18 years old.
Additionally, you should know that, in patients under 18 years old, there is a higher risk of adverse effects such as suicidal behavior, suicidal thoughts, and hostility (mainly aggression, confrontational behavior, and anger) when taking this type of medication.
Despite this, the doctor who prescribes this medication to you may prescribe it to patients under 18 years old when they decide it is the best option for the patient.
If the doctor who prescribes this medication to you has prescribed it to a patient under 18 years old and wants to discuss this decision, please return to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen in these patients under 18 years old who are taking this medication. Additionally, the long-term effects of this medication on safety, growth, maturity, and cognitive and behavioral development have not yet been demonstrated.
Other medications and Desvenlafaxina Neuraxpharm
Inform your doctor or pharmacist that you are using, have used recently, or may need to use any other medication.
It is especially important to inform your doctor if you are taking any of the following medications:
Serotonin syndrome or reactions similar to Neuroleptic Malignant Syndrome (NMS)(NMS)
Rarely, this medication may produce a disorder called serotonin syndrome or reactions similar to NMS that can cause significant changes in brain, muscle, and digestive system function due to high levels of serotonin in the body. This potentially fatal state can occur when taking medications like desvenlafaxine, especially when taken with other medications mentioned above.
See the section “Warnings and precautions” for possible side effects related to serotonin syndrome or reactions similar to NMS.
Changing antidepressant
When switching from one antidepressant to desvenlafaxine, withdrawal symptoms from the initial antidepressant have appeared. Your doctor may reduce your initial antidepressant medication dose gradually to help reduce these symptoms.
Interactions with laboratory tests
Falsely positive results for substances such as phenylcylidine (PCP) and amphetamines may occur in urine tests of patients taking or who have taken desvenlafaxine, even several days after stopping treatment.
Use of Desvenlafaxina Neuraxpharm with food, drinks, and alcohol
This medication's tablets can be taken with or without food.
Avoid taking alcohol while using this medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor before using this medication.
Your doctor or midwife should know that you are taking this medication. When taken during pregnancy, similar medications (SSRIs) may increase the risk of a severe condition for the baby called persistent pulmonary hypertension of the newborn (PPHN), causing the baby to breathe faster and turn blue. These symptoms usually start within the first 24 hours after the baby is born. If your baby has these symptoms, contact your doctor and/or midwife immediately.
If you take Desvenlafaxina Neuraxpharm during pregnancy, inform your doctor and/or midwife, as your baby may experience withdrawal symptoms when born. These symptoms may appear just after birth and may require hospitalization. Among the symptoms are difficulty breastfeeding or respiratory problems. If your baby has these or other symptoms when born and you are concerned, contact your doctor and/or midwife.
If you take Desvenlafaxina in the final stages of pregnancy, there may be an increased risk of heavy vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders.
Your doctor and/or midwife should know that you are taking desvenlafaxine to be able to advise you.
Desvenlafaxine passes into breast milk. There is a risk of effect on the baby. Therefore, do not use this medication during breastfeeding unless your doctor specifically tells you to.
Driving and operating machines
This medication may cause dizziness, drowsiness, and blurred vision.Do not drive or operate tools or machines until you know how this medication affects you.
Follow exactly the administration instructions of this medication as indicated by your doctor.In case of doubt, consult your doctor again.
The recommended dose is 50 mg once a day. Your doctor may increase your dose up to 100 mg once a day or even up to a maximum of 200 mg once a day if necessary.
If you have kidney problems, or a history of kidney problems, consult your doctor as you may need to take a different dose of this medication.
Desvenlafaxina Neuraxpharm should be taken orally, approximately at the same time every day. The tablets should be swallowed whole with liquid, without dividing them, crushing them, chewing them, or dissolving them.
If you take more Desvenlafaxina Neuraxpharmthan you should
Immediately contact your doctor or pharmacist if you take more of this medication than your doctor has prescribed.
In case of overdose or accidental ingestion, consult your doctor or call the Toxicological Information Service, Tel. 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Desvenlafaxina Neuraxpharm
If you have missed a dose, take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and take only one dose, as usual. Do not take a double dose to compensate for the missed dose.
If you interrupt treatment with Desvenlafaxina Neuraxpharm
Do not stop taking Desvenlafaxina, or change the dose, without your doctor's indication, even if you feel better.
If your doctor considers that you no longer need to take desvenlafaxina, you can ask them to reduce the dose gradually before interrupting treatment completely.
It is known that patients experience adverse effects when stopping this medication, especially if they have taken a high dose and for a prolonged period of time or when treatment is interrupted abruptly or the dose is reduced too quickly.
These adverse effects are:mood changes, agitation, sensory changes (tingling or electric shock sensation), confusion, emotional instability, insomnia, hypomania, tinnitus, seizures, dizziness, nausea, headache, fatigue, irritability, diarrhea, anxiety, nightmares, and excessive sweating
Although these symptoms are usually self-limiting, severe withdrawal symptoms have been reported. Therefore, the dose should be reduced gradually whenever possible, under medical supervision, if you and your doctor decide to interrupt treatment with Desvenlafaxina. If you experience any of these or other unpleasant symptoms, consult your doctor.
If you have more questions about the use of this medication, consult your doctor or pharmacist..
Severe side effects
If you notice any of the following signs, inform your doctor immediately or visit the nearest hospital:
List of possible side effects
The side effects and frequency (probability of occurrence) mentioned below have been observed in patients. In general, these side effects occurred more frequently during the first week of treatment.
Very common side effects: affect more than 1 in 10 patients
Common side effects: affect up to 1 in 10 patients
Rare side effects: affect up to 1 in 100 patients
Rare side effects: affect up to 1 in 1000 patients
Unknown frequency: cannot be estimated from available data.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this prospectus.You can also report them directly through theSpanish System for the Pharmacovigilance of Medicinal Products for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after “CAD”.The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or in the trash.Deposit the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, askyour pharmacist how to dispose of the packaging and medications you no longer need.By doing so,you will help protect the environment.
Composition of Desvenlafaxine Neuraxpharm
The active ingredient is desvenlafaxine (as benzoate).
Each tablet contains 50 mg of desvenlafaxine (as benzoate).
The other components are:hypromellose type 2208, 100 Pa.s (E464), microcrystalline cellulose (E460), talc (E553b), stearic acid (E570), magnesium stearate (E470b), anhydrous colloidal silica (E551).
The coating of the 50 mg tablets consists of: Poly(vinyl alcohol) (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b), yellow iron oxides (E172) and red iron oxide (E172).
Appearance of the product and contents of the package
Clear pink-colored, round, biconvex tablets with a diameter of 9.6 ± 0.2 mm.
Packed in Aluminio_PVC/PE/PVdC or Aluminio_OPA/Alu/PVC blisters.
Desvenlafaxine Neuraxpharm 50 mg is available in packs of 10, 20, 28, 30, 50 and 100 tablets.
Only some pack sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
Responsible for manufacturing
PharOS MT Ltd.
HF62X, Hal Far Industrial Estate,
Birzebbugia BBG3000
Malta
This medicinal product is authorized in the Member States of the EEA with the following names:
Germany:Desveneurax 50 mg Retardtabletten
Portugal:Faxilex
Spain:Desvenlafaxine Neuraxpharm 50 mg prolonged-release tablets EFG
Italy:Faxilex
Austria:Desveneurax 50 mg Retardtabletten
Date of the last review of this leaflet:December 2021
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.